We are bringing precision medicine to psychiatry. Our blood test reads each patient's molecular fingerprint to identify their condition, and is built to recommend the treatment most likely to work.
Cardiology has troponin. Oncology has biopsies. Psychiatry, responsible for some of the most consequential diagnoses in medicine, still runs on conversation, paper questionnaires and trial and error.
A misdiagnosis in psychiatry isn't a delay. It's years of the wrong medication, during the most treatable window a patient will ever have.
Psychiatric illness rarely shows up as one abnormal molecule. It shows up as a pattern across many: a molecular fingerprint in the blood. We read that fingerprint from a single blood draw, first to tell conditions apart, and ultimately to recommend the treatment each patient is most likely to respond to.
Schizophrenia, bipolar disorder and major depression, separated with 90%, 82% and 74% accuracy in blinded studies.
Identify patients likely to be treatment resistant before months are lost on medications that won't work.
Separate likely responders from likely non-responders to specific drug classes.
Match each patient's molecular fingerprint to the treatment they're most likely to respond to, so the first prescription is the right one.
Aptamer discovery and deep learning are the upstream tools we use to find and refine each signature. Detection happens in CLIA-certified laboratories today, with a point-of-care assay as the next step.
Instead of searching for one predefined biomarker, we screen billions of short, lab-engineered aptamers to find those that bind disease-specific signatures directly from blood, capturing proteins, metabolites and other circulating molecules antibodies miss.
Our models learn the multi-molecular patterns that separate one psychiatric condition from another and, trained on deeply phenotyped cohorts, predict how a patient is likely to respond to treatment. This is what turns raw molecular data into a clinical answer.
Our first product measures the signature in CLIA-certified laboratories as a laboratory-developed test. Our graphene assay is being built to take the same measurement to the point-of-care.
Treatment-resistant schizophrenia is usually recognised only after at least two medications have failed, which can take years. Our first product is a blood test that tells treatment-resistant from non-treatment-resistant schizophrenia, so patients can reach the right treatment path sooner. It is offered as a laboratory-developed test (LDT), run in CLIA-certified laboratories.
OneCare advances through partnerships. We bring the platform, the molecular signatures and the evidence behind them. Each partner brings the expertise to take them further, in clinical research, laboratory testing or drug development.
Hospitals, health systems and research networks that want to run prospective validation with us, in larger and more diverse cohorts, with longitudinal follow-up to establish predictive and prognostic value.
CLIA-certified laboratories that want to offer our test as a laboratory-developed test.
Drug developers that want to use our signatures to stratify psychiatric trial populations or to co-develop a companion diagnostic.
How we work with pharma →